Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
To evaluate safety and efficacy of combined hepatic arterial infusion (HAIC) of oxaliplatin,
5-fluorouracil and leucovorin and sorafenib in patients with advanced hepatocellular
carcinoma (HCC).